{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:29:46Z","timestamp":1787689786815,"version":"build-2784847793"},"reference-count":81,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Iuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Cluj-Napoca, Romania","award":["646\/23\/11.01.2024"],"award-info":[{"award-number":["646\/23\/11.01.2024"]}]},{"award":["646\/23\/11.01.2024"],"award-info":[{"award-number":["646\/23\/11.01.2024"]}],"id":[{"id":"https:\/\/ror.org\/051h0cw83","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: SGLT2 inhibitors increase hemoglobin and hematocrit in multiple clinical settings, an effect increasingly attributed to stimulation of erythropoiesis rather than hemoconcentration. However, most mechanistic evidence derives from diabetic populations, leaving uncertainty as to whether this response depends on diabetes-related metabolic changes. To evaluate whether dapagliflozin stimulates erythropoiesis in non-diabetic patients with heart failure and to determine whether hematologic changes correlate with renal, cardiac, inflammatory, hepatic, or iron-related parameters. Materials and Methods: In this retrospective observational study, each of 68 non-diabetic heart failure patients served as their own control. Hematologic, renal, cardiac, inflammatory, hepatic, and iron parameters were assessed at three time points: one year prior to dapagliflozin initiation, at baseline, and one year after initiation of therapy. Changes were analyzed using paired tests and correlation analyses. Results: Hemoglobin, hematocrit, and red blood cell count were significantly lower at the baseline compared with values recorded one year before dapagliflozin initiation and increased significantly during the year following treatment (all p &lt; 0.001), while mean corpuscular indices remained stable. Serum iron decreased before treatment and increased significantly after dapagliflozin initiation (p &lt; 0.05 vs. baseline); however, changes in serum iron did not correlate significantly with changes in hemoglobin after treatment. Inflammatory markers showed a modest reduction in C-reactive protein after treatment, while composite inflammatory indices remained largely stable. Liver enzymes showed no significant longitudinal changes. Correlation analyses demonstrated no association between changes in hemoglobin and changes in eGFR (\u03c1 = 0.202, p = 0.098) or NT-proBNP (\u03c1 = \u22120.003, p = 0.981) after treatment. Hematologic variables remained strongly intercorrelated, whereas cross-system correlations were minimal, indicating that erythropoietic stimulation occurred largely independently of renal or cardiac functional trajectories. Conclusions: Dapagliflozin robustly stimulates erythropoiesis in non-diabetic patients with heart failure, independent of improvements in kidney or cardiac function. Although serum iron levels improved after treatment, the absence of a direct correlation with hemoglobin suggests that iron mobilization may act as a permissive rather than a primary driver of erythropoietic response. These findings support the concept that erythropoiesis represents a diabetes-independent pharmacologic action of SGLT2 inhibitors and may involve renal, hepatic, inflammatory, and iron-regulatory pathways beyond those described in diabetic physiology. Dedicated mechanistic studies in non-diabetic populations are warranted.<\/jats:p>","DOI":"10.3390\/medicina62050993","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:19:52Z","timestamp":1779877192000},"page":"993","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Uncoupling Erythropoiesis from Cardiorenal Effects: SGLT2 Inhibition in Non-Diabetic Heart Failure"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4883-3856","authenticated-orcid":false,"given":"Dan Claudiu","family":"M\u0103gureanu","sequence":"first","affiliation":[{"name":"Pharmacology, Toxicology and Clinical Pharmacology, Department of Morphofunctional Sciences, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Victor Babes, No 8, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3279-5384","authenticated-orcid":false,"given":"Ioana Corina","family":"Bocsan","sequence":"additional","affiliation":[{"name":"Pharmacology, Toxicology and Clinical Pharmacology, Department of Morphofunctional Sciences, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Victor Babes, No 8, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-5977","authenticated-orcid":false,"given":"Raluca Maria","family":"Pop","sequence":"additional","affiliation":[{"name":"Pharmacology, Toxicology and Clinical Pharmacology, Department of Morphofunctional Sciences, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Victor Babes, No 8, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3904-2852","authenticated-orcid":false,"given":"Maria Adriana","family":"Neag","sequence":"additional","affiliation":[{"name":"Pharmacology, Toxicology and Clinical Pharmacology, Department of Morphofunctional Sciences, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Victor Babes, No 8, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-2291","authenticated-orcid":false,"given":"Angela","family":"Cozma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3511-2788","authenticated-orcid":false,"given":"Anca Dana","family":"Buzoianu","sequence":"additional","affiliation":[{"name":"Pharmacology, Toxicology and Clinical Pharmacology, Department of Morphofunctional Sciences, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, Victor Babes, No 8, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2213-8587(20)30300-4","article-title":"Effects of Canagliflozin on Anaemia in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Post-Hoc Analysis from the CREDENCE Trial","volume":"8","author":"Oshima","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ejhf.2409","article-title":"Impact of Anaemia and the Effect of Empagliflozin in Heart Failure with Reduced Ejection Fraction: Findings from EMPEROR-Reduced","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ejhf.2132","article-title":"Effect of Dapagliflozin on Anaemia in DAPA-HF","volume":"23","author":"Docherty","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"EVIDoa2300049","DOI":"10.1056\/EVIDoa2300049","article-title":"Dapagliflozin and Anemia in Patients with Chronic Kidney Disease","volume":"2","author":"Koshino","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the Sodium Glucose Co-Transporter 2 Inhibitor Canagliflozin on Plasma Volume in Patients with Type 2 Diabetes Mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a Glucose-Regulating Drug with Diuretic Properties in Subjects with Type 2 Diabetes","volume":"15","author":"Wie","year":"2013","journal-title":"Diabetes. Obes. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102702","DOI":"10.1016\/j.dsx.2022.102702","article-title":"Increase in Hematocrit with SGLT-2 Inhibitors\u2014Hemoconcentration from Diuresis or Increased Erythropoiesis after Amelioration of Hypoxia?","volume":"17","author":"Ekanayake","year":"2023","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","article-title":"Mechanisms of Enhanced Renal and Hepatic Erythropoietin Synthesis by Sodium\u2013Glucose Cotransporter 2 Inhibitors","volume":"44","author":"Packer","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/ajh\/hpae092","article-title":"State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications","volume":"37","author":"Vallon","year":"2024","journal-title":"Am. J. Hypertens."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.2735","article-title":"Effects of Empagliflozin on Erythropoiesis in Heart Failure: Data from the Empire HF Trial","volume":"25","author":"Omar","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2025.03.503","article-title":"Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: The EMPEROR Program","volume":"85","author":"Ferreira","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22396","DOI":"10.1038\/s41598-020-78734-z","article-title":"Dapagliflozin Effects on Haematocrit, Red Blood Cell Count and Reticulocytes in Insulin-Treated Patients with Type 2 Diabetes","volume":"10","author":"Aberle","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/dom.14517","article-title":"Effects of Empagliflozin on Erythropoiesis in Patients with Type 2 Diabetes: Data from a Randomized, Placebo-Controlled Study","volume":"23","author":"Thiele","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12933-023-02027-8","article-title":"Effects of Dapagliflozin and Dapagliflozin-Saxagliptin on Erythropoiesis, Iron and Inflammation Markers in Patients with Type 2 Diabetes and Chronic Kidney Disease: Data from the DELIGHT Trial","volume":"22","author":"Koshino","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"R1009","DOI":"10.1152\/ajpregu.00809.2010","article-title":"The Proximal Tubule in the Pathophysiology of the Diabetic Kidney","volume":"300","author":"Vallon","year":"2010","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wang, H., Zhang, S., and Guo, J. (2021). Lipotoxic Proximal Tubular Injury: A Primary Event in Diabetic Kidney Disease. Front. Med., 8.","DOI":"10.3389\/fmed.2021.751529"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","article-title":"Metabolic Communication by SGLT2 Inhibition","volume":"149","author":"Billing","year":"2024","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000531084","article-title":"Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia","volume":"55","author":"Packer","year":"2024","journal-title":"Am. J. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling\/Autophagy Hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cvr\/cvaa064","article-title":"Critical Examination of Mechanisms Underlying the Reduction in Heart Failure Events with SGLT2 Inhibitors: Identification of a Molecular Link between Their Actions to Stimulate Erythrocytosis and to Alleviate Cellular Stress","volume":"117","author":"Packer","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/dom.14963","article-title":"Alleviation of Functional Iron Deficiency by SGLT2 Inhibition in Patients with Type 2 Diabetes","volume":"25","author":"Packer","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabetes Technol. Ther."},{"key":"ref_31","first-page":"577","article-title":"Kidney Disease in Diabetes Mellitus: Cross-Linking between Hyperglycemia, Redox Imbalance and Inflammation","volume":"112","author":"Amorim","year":"2019","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wu, T., Ding, L., Andoh, V., Zhang, J., and Chen, L. (2023). The Mechanism of Hyperglycemia-Induced Renal Cell Injury in Diabetic Nephropathy Disease: An Update. Life, 13.","DOI":"10.3390\/life13020539"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100344","DOI":"10.1016\/j.metop.2024.100344","article-title":"Anemia in Diabetes Mellitus: Pathogenetic Aspects and the Value of Early Erythropoietin Therapy","volume":"25","author":"Antoniadou","year":"2025","journal-title":"Metab. Open"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Tziastoudi, M., Pissas, G., Golfinopoulos, S., Filippidis, G., Dousdampanis, P., Eleftheriadis, T., and Stefanidis, I. (2023). Sodium\u2013Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review. Life, 13.","DOI":"10.3390\/life13122338"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of Diabetes on the Effects of Sodium Glucose Co-Transporter-2 Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5414\/CN111749","article-title":"Impact of Diabetes on the Effects of SGLT2 Inhibitors on Kidney Outcomes: An Updated Drug\/Dose-Dependent Meta-Analysis","volume":"105","author":"Qian","year":"2025","journal-title":"Clin. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jama.2025.20835","article-title":"Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis","volume":"335","author":"Staplin","year":"2026","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/ndt\/gfae060","article-title":"How Can Inhibition of Glucose and Sodium Transport in the Early Proximal Tubule Protect the Cardiorenal System?","volume":"39","author":"Vallon","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E621","DOI":"10.1152\/ajpendo.00277.2023","article-title":"Novel Perspectives Regarding the Physiologic Mechanisms by Which Gliflozins Induce Reticulocytosis and Erythrocytosis","volume":"325","author":"Heyman","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/jcp.30621","article-title":"Renoprotective Mechanisms of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors against the Progression of Diabetic Kidney Disease","volume":"237","author":"Ravindran","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr. Diab. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E265","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"C525","DOI":"10.1152\/ajpcell.00143.2024","article-title":"Mechanisms of Heart Failure and Chronic Kidney Disease Protection by SGLT2 Inhibitors in Nondiabetic Conditions","volume":"327","author":"Girardi","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000507272","article-title":"Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes","volume":"51","author":"Marathias","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"851","DOI":"10.7326\/M21-4284","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure: A Systematic Review and Meta-Analysis","volume":"175","author":"Zou","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/dom.14986","article-title":"Impact of Baseline Kidney Function on the Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Kidney and Heart Failure Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"25","author":"Maddaloni","year":"2023","journal-title":"Diabetes. Obes. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Reyes-Farias, C.I., Reategui-Diaz, M., Romani-Romani, F., and Prokop, L. (2023). The Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Chronic Kidney Disease with or without Type 2 Diabetes Mellitus on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0295059"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/dom.15122","article-title":"Stabilization of Kidney Function and Reduction in Heart Failure Events with Sodium-Glucose Co-Transporter 2 Inhibitors: A Meta-Analysis and Meta-Regression Analysis","volume":"25","author":"Keidai","year":"2023","journal-title":"Diabetes. Obes. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/dom.15171","article-title":"Improving Heart Failure Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors in Different Patient Groups","volume":"25","author":"Jhund","year":"2023","journal-title":"Diabetes. Obes. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1016\/j.amjmed.2020.04.006","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials","volume":"133","author":"Kumar","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","article-title":"Mechanisms of Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction","volume":"44","author":"Pandey","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41574-025-01170-4","article-title":"Cardiometabolic and Renal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors","volume":"21","author":"Lee","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hanke, J., Romejko, K., and Niemczyk, S. (2025). Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes and Beyond: Mechanisms, Pleiotropic Benefits, and Clinical Use-Reviewing Protective Effects Exceeding Glycemic Control. Molecules, 30.","DOI":"10.3390\/molecules30204125"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/ejhf.2731","article-title":"How Can Sodium-Glucose Cotransporter 2 Inhibitors Stimulate Erythrocytosis in Patients Who Are Iron-Deficient? Implications for Understanding Iron Homeostasis in Heart Failure","volume":"24","author":"Packer","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s43440-022-00442-4","article-title":"Sodium-Glucose Cotransporter Inhibitors and Kidney Fibrosis: Review of the Current Evidence and Related Mechanisms","volume":"75","author":"Afsar","year":"2023","journal-title":"Pharmacol. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"102934","DOI":"10.1016\/j.dsx.2023.102934","article-title":"Antifibrotic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: A Comprehensive Review","volume":"18","author":"Shakour","year":"2024","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cytogfr.2025.05.007","article-title":"Exploring Inflammatory and Fibrotic Mechanisms Driving Diabetic Nephropathy Progression","volume":"84","author":"Ansari","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"166044","DOI":"10.1016\/j.bbadis.2020.166044","article-title":"Diabetic Fibrosis","volume":"1867","author":"Tuleta","year":"2021","journal-title":"Biochim. Biophys. Acta. Mol. Basis Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1681\/ASN.2020010010","article-title":"Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors","volume":"31","author":"Packer","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A Kidney Perspective on the Mechanism of Action of Sodium Glucose Co-Transporter 2 Inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A Sodium-Glucose Cotransporter 2 Inhibitor Attenuates Renal Capillary Injury and Fibrosis by a Vascular Endothelial Growth Factor-Dependent Pathway after Renal Injury in Mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Shirakawa, K., and Sano, M. (2020). Sodium-Glucose Co-Transporter 2 Inhibitors Correct Metabolic Maladaptation of Proximal Tubular Epithelial Cells in High-Glucose Conditions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207676"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"16459","DOI":"10.1038\/s41598-024-65410-9","article-title":"SGLT2 Inhibitors Attenuate Endothelial to Mesenchymal Transition and Cardiac Fibroblast Activation","volume":"14","author":"Schmidt","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1002\/jcp.30851","article-title":"Sodium-Glucose Co-Transporter 2 Inhibitors and Hematopoiesis","volume":"237","author":"Yaribeygi","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jchf.2022.10.004","article-title":"Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure","volume":"11","author":"Packer","year":"2023","journal-title":"JACC. Heart Fail."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ejhf.2992","article-title":"Erythropoietic Response after Intravenous Iron in Patients with Heart Failure and Reduced Ejection Fraction with and without Background Treatment with Sodium-Glucose Cotransporter 2 Inhibitors","volume":"25","author":"Marques","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","article-title":"Erythroferrone Inhibits the Induction of Hepcidin by BMP6","volume":"132","author":"Arezes","year":"2018","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"105374","DOI":"10.1016\/j.jbc.2023.105374","article-title":"Characterization of Erythroferrone Structural Domains Relevant to Its Iron-Regulatory Function","volume":"299","author":"Srole","year":"2023","journal-title":"J. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Correnti, M., Gammella, E., Cairo, G., and Recalcati, S. (2022). Iron Mining for Erythropoiesis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105341"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1002\/jcp.30247","article-title":"Erythroferrone Structure, Function, and Physiology: Iron Homeostasis and Beyond","volume":"236","author":"Srole","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.freeradbiomed.2018.07.003","article-title":"Erythropoietic Regulators of Iron Metabolism","volume":"133","author":"Ganz","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.jacc.2024.07.013","article-title":"Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program","volume":"84","author":"Packer","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Sano, M. (2023). A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065983"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Wang, D., Liu, J., Zhong, L., Li, S., Zhou, L., Zhang, Q., Li, M., and Xiao, X. (2022). The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Biomarkers of Inflammation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1045235"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00018-022-04289-z","article-title":"Anti-Inflammatory Effect of SGLT-2 Inhibitors via Uric Acid and Insulin","volume":"79","author":"Olivieri","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Feij\u00f3o-Band\u00edn, S., Arag\u00f3n-Herrera, A., Otero-Santiago, M., Anido-Varela, L., Mora\u00f1a-Fern\u00e1ndez, S., Taraz\u00f3n, E., Rosell\u00f3-Llet\u00ed, E., Portol\u00e9s, M., Gualillo, O., and Gonz\u00e1lez-Juanatey, J.R. (2022). Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105634"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Lanser, L., Fuchs, D., Kurz, K., and Weiss, G. (2021). Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment. Nutrients, 13.","DOI":"10.3390\/nu13113732"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of Inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/993\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:33:03Z","timestamp":1779877983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":81,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["medicina62050993"],"URL":"https:\/\/doi.org\/10.3390\/medicina62050993","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]}}}